Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05039515




Registration number
NCT05039515
Ethics application status
Date submitted
2/09/2021
Date registered
9/09/2021
Date last updated
27/06/2024

Titles & IDs
Public title
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Scientific title
A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants.
Secondary ID [1] 0 0
2020-002858-24
Secondary ID [2] 0 0
D-CA-60130-452
Universal Trial Number (UTN)
Trial acronym
FALKON
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fibrodysplasia Ossificans Progressiva 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Injuries and Accidents 0 0 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - IPN60130
Treatment: Drugs - IPN60130
Treatment: Drugs - Placebo

Experimental: IPN60130 high dosage - Oral capsule, swallowed whole or sprinkled onto food, once daily

Experimental: IPN60130 low dosage - Oral capsule, swallowed whole or sprinkled onto food, once daily

Placebo comparator: Placebo - Oral capsule, swallowed whole or sprinkled onto food, once daily


Treatment: Drugs: IPN60130
Immediate-release capsule containing high dose of the drug substance.

Treatment: Drugs: IPN60130
Immediate-release capsule containing low dose of the drug substance.

Treatment: Drugs: Placebo
Placebo will be supplied as powder filled hard capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized change in HO volume as assessed by low-dose WBCT (excluding the head) in treated participants receiving IPN60130 compared with placebo.
Timepoint [1] 0 0
From baseline to 12 months
Primary outcome [2] 0 0
Incidence of Adverse Events / Serious Adverse Events (AEs/SAE)
Timepoint [2] 0 0
From baseline until the end of study (63 months)
Primary outcome [3] 0 0
Change from baseline in clinically significant abnormal values in laboratory parameters (haematology, biochemistry, and urinalysis)
Timepoint [3] 0 0
From baseline until the end of study (63 months)
Primary outcome [4] 0 0
Change from baseline in physical examination findings
Timepoint [4] 0 0
From baseline until the end of study (63 months)
Primary outcome [5] 0 0
Change from baseline in clinically significant vital signs
Timepoint [5] 0 0
From baseline until the end of study (63 months)
Primary outcome [6] 0 0
Change from baseline in clinically significant Electrocardiogram (ECG) readings
Timepoint [6] 0 0
From baseline until the end of study (63 months)
Secondary outcome [1] 0 0
Change in HO volume of new HO lesions as detected by WBCT in participants receiving IPN60130 compared with placebo recipients
Timepoint [1] 0 0
From baseline up to 12 months
Secondary outcome [2] 0 0
Change in number of HO lesions by WBCT in participants receiving IPN60130 compared with placebo recipients
Timepoint [2] 0 0
From baseline up to 12 months
Secondary outcome [3] 0 0
Flare-up rate and number of flare-up days in participants receiving IPN60130 compared with placebo recipients
Timepoint [3] 0 0
From baseline up to 12 months
Secondary outcome [4] 0 0
The number of body regions with new HO in participants receiving IPN60130 compared with placebo recipients
Timepoint [4] 0 0
From baseline up to 12 months
Secondary outcome [5] 0 0
Change in pain intensity
Timepoint [5] 0 0
From baseline up to 12 months
Secondary outcome [6] 0 0
The proportion of participants with any new HO in participants receiving IPN60130 compared with placebo recipients
Timepoint [6] 0 0
From baseline up to 12 months
Secondary outcome [7] 0 0
Change from baseline in HO volume as detected by WBCT in participants receiving IPN60130 compared with placebo recipients and with participants receiving the standard of care in the Natural history study (NHS)
Timepoint [7] 0 0
From baseline up to 60 months
Secondary outcome [8] 0 0
Change from baseline in Cumulative Analogue Joint Involvement Scale for FOP (CAJIS) by treatment arm compared with placebo recipients and participants receiving the standard of care in the NHS across all available timepoints
Timepoint [8] 0 0
From baseline up to 60 months
Secondary outcome [9] 0 0
Change in the FOP Physical Function Questionnaire (FOP-PFQ) by treatment arm compared with placebo recipients and participants receiving the standard of care in the NHS from baseline across all available timepoints
Timepoint [9] 0 0
From baseline up to 60 months
Secondary outcome [10] 0 0
Pharmacokinetic (PK) parameter: Cmax of IPN60130
Timepoint [10] 0 0
From baseline up to Month 24
Secondary outcome [11] 0 0
PK parameter: AUC of IPN60130
Timepoint [11] 0 0
Every 6 months up to Month 24
Secondary outcome [12] 0 0
PK parameter: Ctrough of IPN60130
Timepoint [12] 0 0
Every 6 months up to Month 24
Secondary outcome [13] 0 0
PK parameter: Cmin of IPN60130
Timepoint [13] 0 0
Every 6 months up to Month 24
Secondary outcome [14] 0 0
Assessment of the exposure-response relationship
Timepoint [14] 0 0
From baseline up to 60 months

Eligibility
Key inclusion criteria
Key

* Participants must be at least 5 years of age, to be confirmed (entry for younger paediatric participants <15 years of age will only be once safety in adult and older paediatric participants =15 years of age has been established) at the time of signing the informed participant/parent consent and, for participants who are minors, age-appropriate assent.
* Participants must be at least 15 years of age at the time of signing the informed participant/parent consent for the main study and, for participants who are minors, age-appropriate assent
* Participants must be clinically diagnosed with FOP, with the R206H ACVR1 mutation or other FOP variants associated with progressive HO.
* Participants must have disease progression in the preceding year of the screening visit.
* Participants who have participated in a prior clinical study using another investigational product for the treatment of FOP may be enrolled after a washout of at least 5 half-lives of the other investigational product. Participants with prior treatment such as, but not limited to, imatinib, isotretinoin, garetosmab, or palovarotene may be enrolled 30 days after discontinuation or after washout of at least 5 half-lives, whichever is longer.

1. Washout period for palovarotene is 30 days
2. Washout period for garetosmab is 4 months
* Participants must be able to perform pulmonary function tests adequately and reliably.
* Participants must be able to have an adequate echocardiography assessment at screening for evaluation of left ventricular structure and function as defined by the protocol.
* Participants must be accessible for treatment and follow-up and be able to undergo all study procedures. Participants living at distant locations from the investigational site must be able and willing to travel to a site for the initial and all on-site follow-up visits. Participants must be able to undergo low-dose WBCT (excluding head) without sedation.
* Body weight =10 kg.
* Abstinent or using two highly effective forms of birth control. Females must also have a negative blood or urine pregnancy test prior to administration of study drug.
* Participants must be capable of giving written, signed, and dated informed participant/parent consent; and for participants who are minors, age-appropriate assent and/or legal guardian consent (performed according to local regulations)

Key
Minimum age
5 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants with complete heart block and left bundle branch block on screening electrocardiogram.
* Participants with screening echocardiography showing septal or left ventricular free wall thickness >12 mm for adult participants or a z-score >3 compared with population norms for children and adolescent participants or left ventricular ejection fraction (LVEF) <50%.
* Participants with severe mitral or tricuspid regurgitation on echocardiography at screening.
* Participants with significant underlying lung disease requiring supplementary oxygen or forced vital capacity <35% of predicted at screening.
* Participants with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or another significant disease as judged by the investigator.
* Participants with severe hepatic impairment.
* Concomitant medications that are strong inhibitors (including grapefruit juice) or inducers (including St John's Wort) of cytochrome P450 (CYP) 3A4 activity; or kinase inhibitors such as imatinib.
* Prior use in the past year and concomitant use of bisphosphonates for participants in the PET-CT sub study.
* Concurrent participation in another interventional clinical study, or a noninterventional study with radiographic measures or invasive procedures (e.g. collection of blood or tissue samples).
* Amylase or lipase >2× the upper limit of normal (ULN) or with a history of chronic pancreatitis.
* Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5×ULN.
* Participants with hematologic abnormalities:

* Hgb<10g/dL
* Platelets<75,000/mm3
* WBC<2000/mm3
* Participants with coagulation test measurements outside of the normal range at screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/08/2029
Actual
Sample size
Target
98
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal North Shore Hospital - New South Wales - Sidney
Recruitment hospital [2] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
- Sidney
Recruitment postcode(s) [2] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Minnesota
Country [3] 0 0
United States of America
State/province [3] 0 0
Pennsylvania
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
Argentina
State/province [5] 0 0
Buenos Aires
Country [6] 0 0
Belgium
State/province [6] 0 0
Leuven
Country [7] 0 0
Brazil
State/province [7] 0 0
São Paulo
Country [8] 0 0
Canada
State/province [8] 0 0
Edmonton
Country [9] 0 0
Canada
State/province [9] 0 0
Toronto
Country [10] 0 0
China
State/province [10] 0 0
Beijing
Country [11] 0 0
China
State/province [11] 0 0
Guangzhou
Country [12] 0 0
China
State/province [12] 0 0
Shanghai
Country [13] 0 0
Colombia
State/province [13] 0 0
Bogotá
Country [14] 0 0
France
State/province [14] 0 0
Paris
Country [15] 0 0
Germany
State/province [15] 0 0
Köln
Country [16] 0 0
Italy
State/province [16] 0 0
Bologna
Country [17] 0 0
Italy
State/province [17] 0 0
Genoa
Country [18] 0 0
Japan
State/province [18] 0 0
Nagoya
Country [19] 0 0
Japan
State/province [19] 0 0
Tokyo
Country [20] 0 0
Japan
State/province [20] 0 0
Obu
Country [21] 0 0
Korea, Republic of
State/province [21] 0 0
Seoul
Country [22] 0 0
Mexico
State/province [22] 0 0
Ciudad de mexico
Country [23] 0 0
Mexico
State/province [23] 0 0
León
Country [24] 0 0
Netherlands
State/province [24] 0 0
Amsterdam
Country [25] 0 0
Portugal
State/province [25] 0 0
Lisboa
Country [26] 0 0
Spain
State/province [26] 0 0
Pozuelo De Alarcón
Country [27] 0 0
Spain
State/province [27] 0 0
Valencia
Country [28] 0 0
Sweden
State/province [28] 0 0
Umeå
Country [29] 0 0
United Kingdom
State/province [29] 0 0
Manchester
Country [30] 0 0
United Kingdom
State/province [30] 0 0
Stanmore

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Clementia Pharmaceuticals Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Ipsen
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability.

This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head.

Adults and participants 5 years of age or older are also eligible for a sub study to evaluate HO lesions assessed by another type of scan, Fluorine-18-labelled natrium fluoride Positron Emission Tomography-Computed Tomography (\[18F\]NaF PET-CT ).
Trial website
https://clinicaltrials.gov/study/NCT05039515
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ipsen Medical Director
Address 0 0
Ipsen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Ipsen Clinical Study Enquiries
Address 0 0
Country 0 0
Phone 0 0
see email
Fax 0 0
Email 0 0
clinical.trials@ipsen.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05039515